BioCentury
ARTICLE | Clinical News

PG11047: Phase I restarted

August 18, 2008 7:00 AM UTC

Progen restarted an open-label, dose-escalation, U.S. Phase I (47-01-002) trial evaluating PG11047 in combination with various marketed drugs in up to 126 patients. CellGate Inc., which was acquired b...